French drugmaker group Sanofi’s new CEO Olivier Brandicourt (left) speaks with chairman Serge Weinberg during the group’s general meeting in Paris.  Photograph: Eric Piermont/Getty Images

Rebel Sanofi investors made a mark at the drug maker’s annual meeting on Monday as resolutions approving millions of euro paid to attract a new boss a(...)

French drugmaker Sanofi has named Olivier Brandicourt, a Paris-educated doctor and head of Bayer’s healthcare arm, as its chief executive officer.

French drugmaker Sanofi has named Olivier Brandicourt, a Paris-educated doctor and head of Bayer’s healthcare arm, as its chief executive officer.Mr B(...)

Christopher Viehbacher, former Sanofi CEO. Photograph: Dylan Vaughan.

European pharmaceuticals group Sanofi on Thursday said it had agreed to pay €4.44 million in total to ousted chief executive Chris Viehbacher. Mr Vie(...)

Sanofi said the launch of new medicines and vaccines in other fields would help mitigate its dependence on Lantus, which accounts for nearly a fifth of sales

Sanofi, which sacked its chief executive three weeks ago, hopes to launch up to 18 new drugs by the end of 2020, with the potential to reap more than(...)

Christopher Viehbacher, ousted chief executive officer of French pharma group Sanofi. Photographer: Scott Eells/Bloomberg

Sanofi investors said former chief executive Chris Viehbacher, ousted today, paid the price for pushing too hard to make the French drugmaker more int(...)

Sanofi chief executive Chris Viehbacher said China’s ministry of industry and commerce had come to the company’s office in Shenyang, but the reason for the visit was not yet clear.

Chinese officials this week visited a regional office of Sanofi, the French pharmaceutical company, in the latest expansion of investigations of weste(...)

Sanofi, which manufacturers colon cancer drug Zaltrap, is suffering at the hands of generic competition.

Sanofi, France’s largest drugmaker, reported a larger-than-expected, 34 per cent, decline in first-quarter profit, crimped by generic competiti(...)